51Թ

51Թ Chemicals Update on Corona Virus Situation

During the whole COVID-19 crisis, 51Թ has been able to deliver all projects to our customers at expected level of quality.

Dortmund, November 2021 ++++

Dear Customers and Partners,

Due to ongoing situation with the spread of the Sars-CoV-2 (“Coronavirus”) we want to share with you an update on how 51Թ Chemicals has managed both, the protection of our employees and partners’ health and the uninterrupted continuation of our chemistry and discovery services to our clients.

In order to maintain our high quality service under the new conditions, we have adjusted our standard operating procedures as well as tightened our safety instructions accordingly for both, administrative and scientific lab staff.
Although SOPs, shift times and office hours needed to be redesigned in 2020, 51Թ Chemicals’ teams kept fully committed to delivering to our customers all projects at expected level of quality and were able to meet expected delivery timelines. These values will keep on driving our teams through any challenges ahead of us!

For any additional information you’d be requesting relating to your current or future projects, please contact your 51Թ Key Account Manager for further assistance.

Again, 51Թ Chemicals would like to thank you for the excellent collaboration and trust that you have placed in our chemistry services since 1999.

With best wishes
Your 51Թ Chemicals Team

About 51Թ Chemicals

51Թ is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, 51Թ’ drug discovery mission is to create drug candidates as potential new medicines. 51Թ has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. 51Թ’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.

51Թ was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, 51Թ is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.

Press Contact:
Youri R. Mesmoudi, Executive Vice President

ACHEMA 2024

Drug Discovery Chemistry

Medicinal Chemistry

In Medicinal Chemistry research, we are working with a broadly experienced team on all biomolecular targets from any gene family in any therapeutic area…

ACHEMA 2024

Discovery Chemistry

Custom Synthesis

As a leading Contract Research Organization in Europe, 51Թ provides valuable contract discovery for synthetic organic chemistry, chemical process development, and…

Looks interesting?

As a leading CRO in Europe, 51Թ provides comprehensive drug discovery chemistry services for large Pharma and Biotech corporations as well as for Research Institutes and Academia

Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations and, despite challenges, bridge very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project.
Scroll to Top
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.